---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-045663"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:02:50.840585+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q4 net loss $0.92/sh; cash $466M; board adds McCormick; acoramidis data mid-2023

## Summary
- Net loss attributable to common stockholders $137.6M in Q4 ($0.92/sh); full year $481.2M ($3.26/sh).
- Cash, equivalents, marketable securities $466.2M at Dec 31, 2022, down from $787.7M; provides runway into 2024.
- Phase 3 ATTRibute-CM trial of acoramidis for ATTR-CM topline data expected mid-2023.
- Phase 2 PROPEL 2 infigratinib cohort 5 data expected March 2023; Phase 3 initiation planned 2023.
- Board changes: Richard Scheller and Brenton Saunders resigned; Frank McCormick appointed to board.

## SEC filing metadata
- accession: 0001193125-23-045663
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/d472572d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-045663
- JSON: https://secwatch.observer/filing/0001193125-23-045663.json
- Plain text: https://secwatch.observer/filing/0001193125-23-045663.txt

## Key facts
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for the full year ended December 31, 2022.
  - Period: the full year ended December 31, 2022
  - Result: reported results
  source text: BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm
- Executive change
  Richard H. Scheller resigned as Director at BridgeBio Pharma, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm
- Executive change
  Brenton L. Saunders resigned as Director at BridgeBio Pharma, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm
- Executive change
  Frank McCormick was appointed as Director at BridgeBio Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 23, 2023, the Company announced that Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has been appointed by the Board to serve as a director of the Company and fill the vacancy created by the resignation of Dr. Scheller.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312523045663/0001193125-23-045663-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.